Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Fauser

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|July 25, 1998
Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patientsN Basara, W I Blau, E Römer, et al.
Bone Marrow Transplantation|February 2, 2000
Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplantI W Blau, N Basara, M Bischoff, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|February 1, 1988
T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host diseaseA A Fauser, C Shustik, A Langleben, et al.
American Journal of Clinical Oncology|April 1, 1994
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study GroupT Conroy, P Cappelaere, M Fabbro, et al.
Bone Marrow Transplantation|March 13, 2001
Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center studyI W Blau, N Basara, G Lentini, et al.
Annals of Hematology|March 4, 2003
Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cellsCh Thiede, K Lutterbeck, U Oelschlägel, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1996
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study GroupA A Fauser, B Duclos, A Chemaissani, et al.
Bone Marrow Transplantation|February 1, 1995
Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantationN Schmitz, P Dreger, A R Zander, et al.
Blood|December 1, 1995
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrowD von Laer, U Meyer-Koenig, A Serr, et al.
Blood|November 15, 1994
A controlled trial of recombinant human erythropoietin after bone marrow transplantationH Link, M A Boogaerts, A A Fauser, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|July 25, 1998
Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patientsN Basara, W I Blau, E Römer, et al.
Bone Marrow Transplantation|February 2, 2000
Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplantI W Blau, N Basara, M Bischoff, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale|February 1, 1988
T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host diseaseA A Fauser, C Shustik, A Langleben, et al.
American Journal of Clinical Oncology|April 1, 1994
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study GroupT Conroy, P Cappelaere, M Fabbro, et al.
Bone Marrow Transplantation|March 13, 2001
Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center studyI W Blau, N Basara, G Lentini, et al.
Annals of Hematology|March 4, 2003
Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cellsCh Thiede, K Lutterbeck, U Oelschlägel, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 1996
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study GroupA A Fauser, B Duclos, A Chemaissani, et al.
Bone Marrow Transplantation|February 1, 1995
Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantationN Schmitz, P Dreger, A R Zander, et al.
Blood|December 1, 1995
Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrowD von Laer, U Meyer-Koenig, A Serr, et al.
Blood|November 15, 1994
A controlled trial of recombinant human erythropoietin after bone marrow transplantationH Link, M A Boogaerts, A A Fauser, et al.
Pageof 10